IRF7 Protein

📖 Wiki Page

protein1242 wordssynced 2026-04-02

IRF7 Protein

...

IRF7 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">IRF7 Protein</th>
</tr>
<tr>
<td class="label">Site</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">Ser471</td>
<td>TBK1/IKKε</td>
</tr>
<tr>
<td class="label">Ser472</td>
<td>TBK1/IKKε</td>
</tr>
<tr>
<td class="label">Ser475</td>
<td>TBK1/IKKε</td>
</tr>
<tr>
<td class="label">Ser477</td>
<td>TBK1/IKKε</td>
</tr>
<tr>
<td class="label">Ser479</td>
<td>TBK1/IKKε</td>
</tr>
<tr>
<td class="label">Isoform</td>
<td>Amino Acids</td>
</tr>
<tr>
<td class="label">IRF7A</td>
<td>503</td>
</tr>
<tr>
<td class="label">IRF7B</td>
<td>458</td>
</tr>
<tr>
<td class="label">IRF7C</td>
<td>332</td>
</tr>
<tr>
<td class="label">IRF7E</td>
<td>506</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">TLR7/9</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">MyD88</td>
<td>Adaptor</td>
</tr>
<tr>
<td class="label">IRAK1/4</td>
<td>Kinases</td>
</tr>
<tr>
<td class="label">TRAF6</td>
<td>Ubiquitination</td>
</tr>
<tr>
<td class="label">TBK1/IKKα</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">IRF3</td>
<td>Cooperation</td>
</tr>
<tr>
<td class="label">IRF5</td>
<td>Cooperation</td>
</tr>
<tr>
<td class="label">p300/CBP</td>
<td>Co-activator</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">[Neurons](/entities/neurons)</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">[Microglia](/entities/microglia)</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Astrocytes](/entities/astrocytes)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">pDCs</td>
<td>Very Low</td>
</tr>
<tr>
<td class="label">Oligodendrocytes</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">59 edges</a></td>
</tr>
</table>

Introduction

Interferon Regulatory Factor 7 (IRF7) is the master regulator of type I interferon (IFN-α/β) gene expression and plays a crucial role in the innate immune response. While IRF3 initiates the first wave of interferon production, IRF7 is responsible for the amplification of type I interferon responses, making it essential for robust antiviral immunity. In the context of neurodegenerative diseases, IRF7 has emerged as a key contributor to chronic neuroinflammation, with dysregulated IRF7 signaling implicated in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other disorders. [@irf]

Official Symbol: IRF7 [@irfa] Official Full Name: Interferon Regulatory Factor 7 [@type] Molecular Weight: ~55 kDa (isoform 1), ~50 kDa (isoform 2/3) [@irfb] Cellular Location: Cytoplasm (inactive), Nucleus (active) [@microglial] Gene: IRF7 (Chromosome 11p15.5) [@tlrirf] UniProt ID: Q13435

Overview

IRF7 is expressed predominantly in plasmacytoid dendritic cells (pDCs), but is also expressed in neurons, astrocytes, [microglia](/cell-types/microglia-neuroinflammation), and other cell types in the central nervous system. Unlike IRF3, which is constitutively expressed, IRF7 expression is induced by type I interferons, creating a positive feedback loop that amplifies the interferon response.

The unique ability of IRF7 to induce multiple IFN-α subtypes (rather than just IFN-β like IRF3) makes it central to the antiviral immune response. However, this same amplification mechanism can contribute to chronic inflammation when dysregulated.

Protein Structure

IRF7 contains several distinct structural domains:

DNA-Binding Domain (DBD)

Located at the N-terminus (amino acids 1-130)
Contains five conserved tryptophan repeats
Binds to ISRE sequences with high affinity
Essential for DNA binding and transcriptional activation

Transcription Activation Domain (TAD)

Located at the C-terminus (amino acids 247-503)
Mediates interaction with transcriptional co-activators
Contains multiple serine residues subject to phosphorylation

Serine-Rich Region

Auto-Inhibitory Region

Located between DBD and TAD
Maintains inactive state in absence of activation
Undergoes conformational change upon phosphorylation

Isoforms

Molecular Function

Activation Mechanism

The IRF7 activation pathway involves:

Pattern Recognition Receptor Activation

TLR7/8 detect single-stranded RNA in endosomes
TLR9 detects unmethylated CpG DNA
RIG-I detects viral RNA in cytoplasm

MyD88-Dependent Signaling

TLR7/8/9 recruit MyD88 adaptor protein
IRAK1 and IRAK4 kinases activated
TRAF6 ubiquitinates downstream targets

IRF7 Phosphorylation

TBK1 and IKKα phosphorylate IRF7
Multiple serine residues phosphorylated
Causes conformational change and dimerization

Nuclear Translocation

IRF7 forms homodimers or heterodimers with IRF3
Dimers translocate to nucleus
Bind to ISRE and activate transcription

Type I IFN Amplification

IRF7's key function is amplifying the interferon response:

Induces expression of multiple IFN-α subtypes (α1, α2, α4, α5, α6, α7, α8, α10, α14, α16, α17, α21)
Potentiates IFN-β expression
Activates broad ISG expression
Creates positive feedback loop

Immune Cell Functions

Plasmacytoid Dendritic Cells (pDCs)

Major producers of type I IFN
IRF7 essential for pDC development and function
Critical for antiviral immunity

B Cell Function

Regulates immunoglobulin class switching
Affects plasma cell differentiation

Natural Killer Cells

Modulates NK cell activity
Affects cytotoxic function

Pathway Interactions

Innate Immune Signaling

Cross-talk Pathways

[NF-κB](/entities/nf-kb): IRF7 can induce NF-κB-dependent genes
STAT Pathway: Type I IFN signaling via STAT1/2
cGAS-[STING](/proteins/sting-protein): Upstream DNA sensing pathway

Role in Neurodegeneration

Alzheimer's Disease

IRF7 plays a significant role in AD pathogenesis:

Chronic Neuroinflammation

[Aβ](/proteins/amyloid-beta) oligomers activate IRF7 in microglia and astrocytes
Leads to sustained production of pro-inflammatory cytokines
Creates self-perpetuating inflammatory cycle

Type I IFN Signature

Elevated IFN-α and ISGs observed in AD brain
IRF7-dependent amplification contributes to chronic type I IFN
Correlates with disease severity and progression

Microglial Activation

IRF7 regulates microglial phenotypic switching
Modulates phagocytic activity
Affects clearance of Aβ

Therapeutic Implications

IRF7 inhibitors may reduce harmful neuroinflammation
Must balance with antiviral immunity
Cell-type specific targeting needed

Parkinson's Disease

In PD, IRF7 contributes to neuroinflammation:

Dopaminergic Neuron Vulnerability

[α-Synuclein](/proteins/alpha-synuclein) activates IRF7 pathway
IRF7-dependent inflammation in substantia nigra
Contributes to dopaminergic neuron loss

Microglial IRF7

Enhanced IRF7 activation in PD microglia
Increased pro-inflammatory cytokine production
Links peripheral immunity to CNS inflammation

LRRK2 Interaction

LRRK2 mutations affect IRF7 regulation
May explain inflammatory component of LRRK2-PD

Amyotrophic Lateral Sclerosis

IRF7 in ALS:

Motor Neuron Environment

IRF7 activation in astrocytes and microglia
Contributes to non-cell autonomous toxicity
Inflammatory milieu damages motor neurons

[TDP-43](/proteins/tdp-43) Pathology

[TDP-43](/mechanisms/tdp-43-proteinopathy) aggregates associated with IRF7 dysregulation
Altered interferon response in ALS

Other Neurodegenerative Conditions

Huntington's Disease: IRF7 in striatal neurodegeneration
Multiple Sclerosis: IRF7 in demyelination
Frontotemporal Dementia: IRF7 dysregulation

Expression in the Brain

Therapeutic Targeting

Small Molecule Approaches

IRF7 Inhibitors

Block IRF7 phosphorylation
Reduce IFN-α amplification
Potential for neuroinflammation modulation

TLR7/9 Antagonists

Upstream inhibition
Reduce IRF7 activation
Clinical trials in autoimmune disease

Kinase Inhibitors

TBK1/IKKα inhibitors
Downstream of TLRs
Broader immune modulation

Biological Therapies

Anti-IFN-α Antibodies

Neutralize downstream effector
May reduce chronic inflammation

MicroRNA Modulation

miR-155 regulates IRF7
Therapeutic potential

Challenges

Essential for antiviral immunity
Balancing inflammation and protection
Cell-type specific delivery
[Blood-brain barrier](/entities/blood-brain-barrier) penetration

Research Directions

Current research areas:

Biomarkers

IRF7 phosphorylation status
IFN-α levels in CSF
ISG signatures

Cell-Specific Mechanisms

Neuron-specific IRF7 functions
Microglial IRF7 in disease

Therapeutic Development

Optimized IRF7 modulators
Targeted delivery systems

History

Key milestones in IRF7 research:

1997: IRF7 cloned and characterized
2000s: Master regulator of type I IFN established
2010s: Role in autoimmunity discovered
2020s: Link to neurodegeneration explored

Background

The study of Irf7 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

IRF7 Protein

IRF7 Protein

IRF7 Protein

Introduction

Overview

Protein Structure

DNA-Binding Domain (DBD)

Transcription Activation Domain (TAD)

Serine-Rich Region

Auto-Inhibitory Region

Isoforms

Molecular Function

Activation Mechanism

Type I IFN Amplification

Immune Cell Functions

Pathway Interactions

Innate Immune Signaling

Cross-talk Pathways

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Other Neurodegenerative Conditions

Expression in the Brain

Therapeutic Targeting

Small Molecule Approaches

Biological Therapies

Challenges

Research Directions

History

Background

See Also